文献速递皮肤肿瘤

MIA前哨淋巴结阳性风险预测工具在原发皮肤黑色素瘤患者中的全球适用性验证

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma.
PubMed 文献 · JAMA Dermatol · 2025-01-01

本研究基于四大洲多中心回顾性队列(n=15 731),外部验证澳大利亚黑色素瘤研究所(MIA)前哨淋巴结转移风险计算器。全部6个参数可用时AUC为73.0%(95%CI 70.6%-75.3%),校准良好,更新后95%CI中位收窄超过75%,提示该工具在全球范围黑色素瘤人群中稳健、精确且适用。

要点

  • 6参数完整时AUC为73.0%,缺1-3个可选参数时AUC为70.8%、71.5%、70.1%。
  • 校准截距0.01(95%CI -0.02至0.03),校准斜率1.03(95%CI 0.90-1.16),校准优秀。
  • 版本2保持风险点估计不变,但95%CI中位收窄超过75%,精确性显著提升。

核心结论

  • MIA前哨淋巴结阳性风险计算器在全部6个参数可用时表现最佳,版本2风险点估计不变但95%CI显著收窄。
  • 该计算器稳健、精确,适用于地理分布广泛的黑色素瘤人群。

研究设计与样本

  • 回顾性多中心队列研究,数据来自四大洲,包括丹麦国家黑色素瘤数据库及英国(n=3)、美国(n=2)、新西兰(n=1)、瑞典(n=1)、巴西(n=1)的癌症中心。
  • 纳入年龄≥18岁、因侵袭性原发皮肤黑色素瘤行前哨淋巴结活检且具备前哨淋巴结状态、诊断时年龄、Breslow厚度和黑色素瘤亚型数据的患者(n=15 731)。

主要发现

  • 全部6个参数可用的子集(n=4989)中,AUC为73.0%(95%CI 70.6%-75.3%)。
  • 缺失1、2或3个可选参数时,AUC分别为70.8%、71.5%和70.1%。
  • 校准优秀,截距和校准斜率分别为0.01(95%CI -0.02至0.03)和1.03(95%CI 0.90-1.16)。
  • 更新后的95%CI范围显著收窄,中位缩减超过75%。

关键数值与推荐

  • 完整6参数模型AUC为73.0%(95%CI 70.6%-75.3%),基于全部6个参数可用的4989例患者。
  • 缺失1、2、3个可选参数时AUC分别为70.8%、71.5%、70.1%。
  • 校准截距0.01(95%CI -0.02至0.03),校准斜率1.03(95%CI 0.90-1.16)。
  • 更新后95%CI中位收窄超过75%。

临床怎么用

  • 在临床中可使用MIA前哨淋巴结阳性风险计算器(版本2)对原发皮肤黑色素瘤患者进行个体化前哨淋巴结转移风险预测。
  • 优先在6个标准临床病理参数齐全时使用该工具,以获得最佳预测性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator provides estimates of positivity for individual patients based on 6 standard clinicopathological parameters and the full 6-parameter model has been externally validated previously using US data. However, given its geographically widespread use, further validation is required to ensure its applicability to other populations. OBJECTIVE: To further externally validate the MIA SN metastasis risk calculator and increase its precision by refinement of the 95% CIs. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multicenter cohort study was carried out using data from 4 continents, including the national Danish Melanoma Database and cancer centers in the UK (n = 3), US (n = 2), New Zealand (n = 1), Sweden (n = 1), and Brazil (n = 1). All patients aged 18 years or older who had an SN biopsy performed for an invasive primary cutaneous melanoma and data available on the following parameters: SN status, patient age at diagnosis, Breslow thickness, and melanoma subtype were included (n = 15 731). Available data were also collected on ulceration status, lymphovascular invasion, and the tumor mitotic rate. Data were collected between July 2021 and December 2023, and the analysis was conducted between January 2024 and June 2024. MAIN OUTCOMES AND MEASURES: The primary outcome was the area under the curve (AUC) of the receiver operating characteristics for the full (6-parameter) risk prediction model. Secondary outcomes were the AUCs for each country and for the limited models (3-5 parameters), the model calibration, and the recalculated 95% CIs for the models. Decision curve analysis was performed to assess the tool's clinical utility. RESULTS: The whole pooled cohort consisted of 15 731 patients; 4989 had all 6 parameters available. The AUC was 73.0% (95% CI, 70.6%-75.3%) in the subset with all 6 parameters available, and 70.8%, 71.5%, and 70.1% when 1, 2, or 3 optional parameters were missing, respectively. Calibration was excellent, with an intercept and calibration slope of 0.01 (95% CI, -0.02 to 0.03) and 1.03 (95% CI, 0.90-1.16), respectively. The updated 95% CI ranges were substantially tighter, with a median reduction of more than 75%. CONCLUSIONS AND RELEVANCE: This study found that the MIA SN-positivity calculator performed best with all 6 parameters and has been significantly improved (version 2), with the same risk point estimates but much tighter 95% CIs. These results demonstrated that the calculator was robust, precise, and applicable to geographically widespread melanoma populations.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lo SN, Gjorup C, Chakera AH, et al. Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma. JAMA Dermatol. 2025. PMID: 40202725. doi:10.1001/jamadermatol.2025.0318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。